Next Article in Journal
BRCA2 and Other DDR Genes in Prostate Cancer
Previous Article in Journal
Arsenic Trioxide and (−)-Gossypol Synergistically Target Glioma Stem-Like Cells via Inhibition of Hedgehog and Notch Signaling
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Cancers 2019, 11(3), 351; https://doi.org/10.3390/cancers11030351

Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood

1
Federal Research Center “Krasnoyarsk Science Center of the Siberian Branch of the Russian Academy of Science”, Krasnoyarsk 660036, Russia
2
Laboratory for Biomolecular and Medical Technologies, Krasnoyarsk State Medical University named after prof. V.F. Voino-Yasenecki, Krasnoyarsk 660022, Russia
3
Krasnoyarsk Regional Clinical Cancer Center named after A.I. Kryzhanovsky, Krasnoyarsk 660133, Russia
4
Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, ON K1N 6N5, Canada
5
Laboratory of Advanced Materials and Technology, Siberian Physical-Technical Institute of Tomsk State University, Tomsk 634050, Russia
*
Authors to whom correspondence should be addressed.
Received: 6 February 2019 / Revised: 7 March 2019 / Accepted: 8 March 2019 / Published: 12 March 2019
(This article belongs to the Special Issue New Biomarkers in Cancers)
Full-Text   |   PDF [6308 KB, uploaded 12 March 2019]   |  

Abstract

We selected DNA aptamers to the epithelial cell adhesion molecule (EpCAM) expressed on primary lung cancer cells isolated from the tumors of patients with non-small cell lung cancer using competitive displacement of aptamers from EpCAM by a corresponding antibody. The resulting aptamers clones showed good nanomolar affinity to EpCAM-positive lung cancer cells. Confocal microscopy imaging and spectral profiling of lung cancer tissues confirmed the same protein target for the aptamers and anti-EpCAM antibodies. Furthermore, the resulted aptamers were successfully applied for isolation and detection of circulating tumor cells in clinical samples of peripheral blood of lung cancer patients. View Full-Text
Keywords: aptamers; SELEX (Systematic evolution of ligands by exponential enrichment); EpCAM; non-small-cell lung cancer; circulating tumor cells; blood aptamers; SELEX (Systematic evolution of ligands by exponential enrichment); EpCAM; non-small-cell lung cancer; circulating tumor cells; blood
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Zamay, G.S.; Kolovskaya, O.S.; Ivanchenko, T.I.; Zamay, T.N.; Veprintsev, D.V.; Grigorieva, V.L.; Garanzha, I.I.; Krat, A.V.; Glazyrin, Y.E.; Gargaun, A.; Lapin, I.N.; Svetlichnyi, V.A.; Berezovski, M.V.; Kichkailo, A.S. Development of DNA Aptamers to Native EpCAM for Isolation of Lung Circulating Tumor Cells from Human Blood. Cancers 2019, 11, 351.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top